Ocular Therapeutix, Inc. (OCUL) Revenue by Segment & Business Profile
Product was 99.7% of Ocular Therapeutix, Inc.'s revenue across the 2 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
OCULOcular Therapeutix, Inc.Follow OCUL — free
—
Price chart with a free account
- Market cap
- 1.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
What the company does
Ocular Therapeutix, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: Product (100%), Collaboration Revenue (0%). Trailing twelve-month revenue: $52.1 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Commercial therapies
Ocular Therapeutix, Inc. — questions
- What does Ocular Therapeutix, Inc. do?
- Ocular Therapeutix, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: Product (100%), Collaboration Revenue (0%). Trailing twelve-month revenue: $52.1 million as of 2026-06-30.
- How does Ocular Therapeutix, Inc. make money?
- By the lines it reports in its SEC filings: Product 99.7%, Collaboration Revenue 0.3% of revenue.
Every figure on this page comes from Ocular Therapeutix, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.